Pandemic 2009 Influenza A (H1N1) virus infection in cancer and hematopoietic stem cell transplant recipients; a multicenter observational study.
Epidemiology
Immunology
Infectious disease (medical specialty)
FOS: Health sciences
Hematopoietic stem cell
03 medical and health sciences
0302 clinical medicine
Observational study
Virology
Health Sciences
Epidemiology and Pathogenesis of Respiratory Viral Infections
Open peer review
Genetics
Disease
Biology
Internal medicine
Cancer
Plant biology
Stem cell
Pandemic
FOS: Clinical medicine
H1N1
Botany
Gastrointestinal Viral Infections and Vaccines Development
Influenza
Virus
3. Good health
Coronavirus disease 2019 (COVID-19)
Infectious Diseases
Haematopoiesis
Influenza A virus
FOS: Biological sciences
Medicine
Influenza Virus Research and Epidemiology
Pandemic influenza
Research Article
DOI:
10.12688/f1000research.5251.2
Publication Date:
2015-08-25T15:25:09Z
AUTHORS (17)
ABSTRACT
Background: During March 2009 a novel Influenza A virus emerged in Mexico. We describe the clinical picture of the pandemic Influenza A (H1N1) Influenza in cancer patients during the 2009 influenza season.Methods: Twelve centers participated in a multicenter retrospective observational study of cancer patients with confirmed infection with the 2009 H1N1 Influenza A virus (influenza-like illness or pneumonia plus positive PCR for the 2009 H1N1 Influenza A virus in respiratory secretions). Clinical data were obtained by retrospective chart review and analyzed. Results: From May to August 2009, data of 65 patients were collected. Median age was 51 years, 57 % of the patients were female. Most patients (47) had onco-hematological cancers and 18 had solid tumors. Cancer treatment mainly consisted of chemotherapy (46), or stem cell transplantation (SCT) (16). Only 19 of 64 patients had received the 2009 seasonal Influenza vaccine. Clinical presentation included pneumonia (43) and upper respiratory tract infection (22). Forty five of 58 ambulatory patients were admitted. Mechanical ventilation was required in 12 patients (18%). Treatment included oseltamivir monotherapy or in combination with amantadine for a median of 7 days. The global 30-day mortality rate was 18%. All 12 deaths were among the non-vaccinated patients. No deaths were observed among the 19 vaccinated patients. Oxygen saturation <96% at presentation was a predictor of mortality (OR 19.5; 95%CI: 2.28 to 165.9).Conclusions: In our cancer patient population, the pandemic 2009 Influenza A (H1N1) virus was associated with high incidence of pneumonia (66%), and 30-day mortality (18.5%). Saturation <96% was significantly associated with death. No deaths were observed among vaccinated patients.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (40)
CITATIONS (2)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....